Global Gambro optimistic its restructuring will pay dividends
This article was originally published in Clinica
Swedish dialysis company Gambro claims its restructuring measures of the past year have resulted in a "well-positioned company in a growth industry". The resulting integration is a "winning formula" for success, according to Mikael Lilius, Gambro's president and CEO, speaking at the company's Capital Markets Day in Lund, Sweden, last week. Imogen Daulby reports.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.